Skip to main content

Advertisement

Table 3 Clinical, laboratory and outcome parameters of RMC cases

From: Clinical benefits of FilmArray meningitis-encephalitis PCR assay in partially-treated bacterial meningitis in Israel

  RMC groupJuly 2017 – June 2018
Number of cases 5
Age (years) 17 ± 11
Male, n (%) 3 (60)
FilmArray ME PCR panel result N. meningitidis (n = 4) S. pneumoniae (n = 1)
Antimicrobials used in initial regimen
 Ceftriaxone 5 (100)
 Ampicillin 1 (20)
 Vancomycin 3 (60)
 Acyclovir 2 (40)
 Doxycycline 1 (20)
Antimicrobials used in final regimen
 Ceftriaxone 5 (100)
 CSF-WBC (cells/μl) 2626 ± 634
 CSF-PMN-(%) 85 ± 4
 CSF-RBC (cells/μl) 5 ± 5
 Glucose ratio (CSF:blood) 56 ± 16
 CSF-Protein (mg/dL) 228 ± 94
 CSF-gram stain positive, n (%) 1 (20), GN cocci
 Blood-WBC (10e3cells/ μl) 24 ± 4
 Blood-CRP (mg/L) 183 ± 23
 Chronic diseases 1 (20), mild developmental delay
 Initial antimicrobial regimen duration (days) 1.6 ± 0.2
 Final antimicrobial regimen duration (days) 7 ± 1.5
 Total antimicrobial treatment duration (days) 8.6 ± 1.4
 Narrow spectrum antibiotic treatment duration (% from total duration) 79 ± 5
 Duration of guideline-adherent antimicrobial regimen (% from total duration) 90 ± 5
 Administration of steroids 3 (60)
 Antimicrobial chemoprophylaxis for close contacts 4 (80)
 In-hospital mortality 0 (0)
 ICU admission 4 (80)
 Length of stay (days) 9.6 ± 2
 Poor functional outcome (mRS ≥ 4) 0 (0)
  1. GP gram positive, CSF cerebrospinal fluid, WBC white blood cells, PMN polymorphonuclear, RBC red blood cells, CRP c-reactive protein